| 1. |
- Georgieva, M. N., et al.
(författare)
-
A tale of two tubeworms: taxonomy of vestimentiferans (Annelida: Siboglinidae) from the Mid-Cayman Spreading Centre
- 2023
-
Ingår i: Invertebrate Systematics. - : CSIRO Publishing. - 1445-5226 .- 1447-2600. ; 37:3, s. 167-91
-
Tidskriftsartikel (refereegranskat)abstract
- The vestimentiferan tubeworm genera Lamellibrachia and Escarpia inhabit deep-sea chemosynthesis-based ecosystems, such as seeps, hydrothermal vents and organic falls, and have wide distributions across the Pacific, Atlantic and Indian Oceans. In 2010-2012 during initial explorations of hydro-thermal vents of the Mid-Cayman Spreading Centre (MCSC), both genera were found to co-occur at the Von Damm Vent Field (VDVF), a site characterised by diffuse flow, therefore resembling a hydrothermal seep'. Here, we erect two new vestimentiferan tubeworm species from the VDVF, Lamellibrachia judigobini sp. nov. and Escarpia tritentaculata sp. nov. Lamellibrachia judigobini sp. nov. differs genetically and morphologically from other Lamellibrachia species, and has a range that extends across the Gulf of Mexico, MCSC, off Trinidad and Tobago, and Barbados, and also across both vents and seeps and 964-3304-m water depth. Escarpia tritentaculata sp. nov. is distinguished from other Escarpia species primarily based on morphology and is known only from vents of the MCSC at 2300-m depth. This study highlights the incredible habitat flexibility of a single Lamellibrachia species and the genus Escarpia, and historic biogeographic connections to the eastern Pacific for L. judigobini sp. nov. and the eastern Atlantic for E. tritentaculata sp. nov.
|
|
| 2. |
- Vedunova, M, et al.
(författare)
-
DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis
- 2022
-
Ingår i: Cell death & disease. - : Springer Science and Business Media LLC. - 2041-4889. ; 13:12, s. 1062-
-
Tidskriftsartikel (refereegranskat)abstract
- Gliomas, the most frequent type of primary tumor of the central nervous system in adults, results in significant morbidity and mortality. Despite the development of novel, complex, multidisciplinary, and targeted therapies, glioma therapy has not progressed much over the last decades. Therefore, there is an urgent need to develop novel patient-adjusted immunotherapies that actively stimulate antitumor T cells, generate long-term memory, and result in significant clinical benefits. This work aimed to investigate the efficacy and molecular mechanism of dendritic cell (DC) vaccines loaded with glioma cells undergoing immunogenic cell death (ICD) induced by photosens-based photodynamic therapy (PS-PDT) and to identify reliable prognostic gene signatures for predicting the overall survival of patients. Analysis of the transcriptional program of the ICD-based DC vaccine led to the identification of robust induction of Th17 signature when used as a vaccine. These DCs demonstrate retinoic acid receptor-related orphan receptor-γt dependent efficacy in an orthotopic mouse model. Moreover, comparative analysis of the transcriptome program of the ICD-based DC vaccine with transcriptome data from the TCGA-LGG dataset identified a four-gene signature (CFH, GALNT3, SMC4, VAV3) associated with overall survival of glioma patients. This model was validated on overall survival of CGGA-LGG, TCGA-GBM, and CGGA-GBM datasets to determine whether it has a similar prognostic value. To that end, the sensitivity and specificity of the prognostic model for predicting overall survival were evaluated by calculating the area under the curve of the time-dependent receiver operating characteristic curve. The values of area under the curve for TCGA-LGG, CGGA-LGG, TCGA-GBM, and CGGA-GBM for predicting five-year survival rates were, respectively, 0.75, 0.73, 0.9, and 0.69. These data open attractive prospects for improving glioma therapy by employing ICD and PS-PDT-based DC vaccines to induce Th17 immunity and to use this prognostic model to predict the overall survival of glioma patients.
|
|
